Compare Adaptive Biotechnologies Corp (ADPT) vs Godaddy Inc (GDDY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Godaddy Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.85 (market cap $3.33B), while Godaddy Inc trades at $87.77 (market cap $11.83B). The key difference: Godaddy Inc is far larger — about 3.6× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Godaddy Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | GDDY | |
|---|---|---|
Market Cap | $3.33B | $11.83B |
Sector | Health | Technology |
52-Week High | $22.37 | $177.04 |
52-Week Low | $10.24 | $75.07 |
Enterprise Value | $3.19B | $14.41B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
GoDaddy (GDDY) trades at $89.32, up 0.92% on the day, with a bullish technical outlook supported by moving averages despite overbought RSI signals. The company exhibits strong profitability with a 17.32% net income margin and consistent earnings beats, though revenue growth is moderating. Recent news highlights a securities class action investigation and optimism around AI resilience, with Q2 2026 results due July 30, 2026.
The stock presents a mixed outlook: analyst consensus is bullish with a $123 price target, but legal risks and high ROE from low equity base warrant caution. Upside hinges on execution amid competitive pressures, while any negative legal developments could pressure shares near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →
